DDInter901 DDInter927
Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Ibutilide {u} (Compound) resembles {v} (Compound) Dronedarone
Ibutilide {u} (Compound) binds {v} (Gene) KCNH7
Ibutilide {u} (Compound) causes {v} (Side Effect) Bradycardia
Ibutilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Ibutilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Ibutilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Ibutilide {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Ibutilide {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Ibutilide (Compound) resembles Dronedarone (Compound)
Ibutilide (Compound) binds KCNH7 (Gene)
Ibutilide (Compound) causes Bradycardia (Side Effect)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Ibutilide may lead to a major life threatening interaction when taken with Mefloquine
Ibutilide may lead to a major life threatening interaction when taken with Anagrelide